[go: up one dir, main page]

CA3000569A1 - Methodes d'utilisation d'oligonucleotides antisens smad7 sur la base de l'expression de biomarqueurs - Google Patents

Methodes d'utilisation d'oligonucleotides antisens smad7 sur la base de l'expression de biomarqueurs Download PDF

Info

Publication number
CA3000569A1
CA3000569A1 CA3000569A CA3000569A CA3000569A1 CA 3000569 A1 CA3000569 A1 CA 3000569A1 CA 3000569 A CA3000569 A CA 3000569A CA 3000569 A CA3000569 A CA 3000569A CA 3000569 A1 CA3000569 A1 CA 3000569A1
Authority
CA
Canada
Prior art keywords
weeks
patient
level
administering
points
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3000569A
Other languages
English (en)
Inventor
Salvatore Bellinvia
Giovanni Monteleone
Gerald Scott BARDEN HORAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
Original Assignee
Nogra Pharma Ltd
Celgene Alpine Investment Co II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd, Celgene Alpine Investment Co II LLC filed Critical Nogra Pharma Ltd
Publication of CA3000569A1 publication Critical patent/CA3000569A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4733—Acute pancreatitis-associated protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des méthodes de traitement de la maladie inflammatoire chronique de l'intestin (MICI) chez un patient atteint d'une MICI à l'aide d'oligonucléotides antisens SMAD7.
CA3000569A 2015-09-30 2016-09-30 Methodes d'utilisation d'oligonucleotides antisens smad7 sur la base de l'expression de biomarqueurs Abandoned CA3000569A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235556P 2015-09-30 2015-09-30
US62/235,556 2015-09-30
PCT/EP2016/073518 WO2017055611A2 (fr) 2015-09-30 2016-09-30 Méthodes d'utilisation d'oligonucléotides antisens smad7 sur la base de l'expression de biomarqueurs

Publications (1)

Publication Number Publication Date
CA3000569A1 true CA3000569A1 (fr) 2017-04-06

Family

ID=57113318

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3000569A Abandoned CA3000569A1 (fr) 2015-09-30 2016-09-30 Methodes d'utilisation d'oligonucleotides antisens smad7 sur la base de l'expression de biomarqueurs

Country Status (4)

Country Link
EP (1) EP3355896A2 (fr)
JP (1) JP2018531936A (fr)
CA (1) CA3000569A1 (fr)
WO (1) WO2017055611A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RU2739302C2 (ru) 2008-11-13 2020-12-22 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
EP3165929A3 (fr) 2011-09-15 2017-06-21 Nogra Pharma Limited Procédés permettant de surveiller la réactivité à une thérapie anti-smad7
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
MA39963A (fr) 2014-05-09 2017-03-15 Nogra Pharma Ltd Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
CA2964667A1 (fr) 2014-10-17 2016-04-21 Nogra Pharma Limited Procedes et compositions pour le traitement d'un sujet au moyen d'un oligonucleotide antisens de smad7
EP3420082A4 (fr) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC Méthodes de traitement de la fibrose intestinale par inhibition de smad7
EP3658155A4 (fr) * 2017-07-28 2021-06-30 Nogra Pharma Limited Procédé de préparation de composés oligonucléotidiques
WO2020077120A1 (fr) * 2018-10-10 2020-04-16 The Board Of Trustees Of The Leland Stanford Junior University Blocage de rgmb pour traiter une maladie intestinale inflammatoire et une colite
CN113226307A (zh) * 2018-11-30 2021-08-06 艾尼纳制药公司 治疗与s1p1受体有关的病况的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
FI20075968A0 (fi) * 2007-12-28 2007-12-28 Licentia Oy Menetelmä immunomodulaattorihoitojen tehokkuuden tarkkailemiseksi
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
RU2739302C2 (ru) * 2008-11-13 2020-12-22 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
BR112013027867A2 (pt) * 2011-04-29 2016-09-06 Bristol Myers Squibb Co "método de detectar o nível de um anticorpo anti-ip10 em amostra, anticorpo monoclonal isolado ou porção de ligação de antígeno do mesmo, linhagem de célula de hibridoma e kit"
EP3165929A3 (fr) * 2011-09-15 2017-06-21 Nogra Pharma Limited Procédés permettant de surveiller la réactivité à une thérapie anti-smad7

Also Published As

Publication number Publication date
JP2018531936A (ja) 2018-11-01
EP3355896A2 (fr) 2018-08-08
WO2017055611A2 (fr) 2017-04-06
WO2017055611A9 (fr) 2017-07-27
WO2017055611A3 (fr) 2017-08-31

Similar Documents

Publication Publication Date Title
CA3000569A1 (fr) Methodes d'utilisation d'oligonucleotides antisens smad7 sur la base de l'expression de biomarqueurs
US10473669B2 (en) Methods for treating inflammatory bowel disease
US20200032264A1 (en) Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
ES2617200T3 (es) Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7
US20190112608A1 (en) Methods of using smad7 antisense oligonucleotides
EP3503882A1 (fr) Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19
US20210207143A1 (en) Methods of Treating Celiac Disease Using SMAD7 Inhibition
JP2017532961A (ja) Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物
JP2017529321A (ja) 炎症性腸疾患を診断ならびに処置するための方法および組成物
US20200237801A1 (en) Methods of using smad7 antisense oligonucleotides based on biomarker expression
JP7162872B2 (ja) 医薬用組成物
NZ719884B2 (en) Methods for monitoring responsiveness to anti-SMAD7 therapy
US20100069343A1 (en) Methods of predicting steroid responsiveness with Il-1RII
NZ622067B2 (en) Methods for monitoring responsiveness to anti-smad7 therapy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220330

FZDE Discontinued

Effective date: 20220330